Is therapeutic hypothermia an effective treatment for hypoxic-ischemic encephalopathy, a type of neurological dysfunction in newborns?

Hypoxic-ischemic encephalopathy (HIE) is one of the leading causes of newborn mortality and morbidity worldwide, and lowering the baby’s body temperature—called therapeutic hypothermia—is often used as a treatment. A review in Developmental Medicine and Child Neurology highlights additional therapies for HIE that are being tested with and without concomitant therapeutic hypothermia.

Neonatal HIE is characterized by neurological dysfunction resulting from inadequate oxygen and blood flow to the brain near the time of birth. Therapeutic hypothermia is an established therapy in high-income countries, but many infants still die or experience neurodevelopmental consequences after treatment. Moreover, in low- and middle-income countries, where the burden of HIE is the highest, therapeutic hypothermia was recently shown to be ineffective.

The new review notes that investigational therapies for HIE include agents that block excessive activation of glutamate receptors, drugs that act as antioxidants or anti-inflammatories, and products that target multiple neuroprotective pathways.

“Therapeutic hypothermia for moderate-to-severe neonatal HIE is one of the success stories in newborn care, but there is an urgent need to identify additional therapies that are effective both with and without therapeutic hypothermia,” said corresponding author Natalie H. Chan, MD, MPH, of the University of California, San Francisco. “Our paper reviews the promising therapies being evaluated in clinical studies that could close the remaining gap in optimizing outcomes in all babies with HIE.”

URL upon publication: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.16184

Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com.

About the Journal
Developmental Medicine and Child Neurology (DMCN) is a multidisciplinary journal that has defined the fields of paediatric neurology and childhood-onset neurodisability for over 60 years. DMCN disseminates the latest clinical research results globally to enhance the care and improve the lives of disabled children and their families.

About Wiley      
Wiley is one of the world’s largest publishers and a trusted leader in research and learning. Our industry-leading content, services, platforms, and knowledge networks are tailored to meet the evolving needs of our customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. We empower knowledge-seekers to transform today’s biggest obstacles into tomorrow’s brightest opportunities. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.